Table 3.
Multivariate Analysis Between Paxlovid Use and Negative Conversion of NAAT
| HR*adj. | 95% CI | p | HR†adj. | 95% CI | p | |
|---|---|---|---|---|---|---|
| Paxlovid use | <0.001 | <0.001 | ||||
| Negative use | 1.00 | — | 1.00 | — | ||
| Use beyond five days of symptom onset | 1.44 | 0.84, 2.44 | 1.68 | 0.92, 3.06 | ||
| Single use within five days of symptom onset | 1.99 | 0.92, 4.32 | 3.37 | 1.41, 8.06 | ||
| Use within five days of symptom onset plus dexamethasone | 14.23 | 4.50, 44.95 | 23.94 | 4.83, 118.62 | ||
| Age | 0.99 | 0.98, 0.99 | 0.009 | 0.99 | 0.98, 0.99 | 0.029 |
| Gender | 0.553 | 0.809 | ||||
| Female | 1.00 | — | 1.00 | — | ||
| Male | 0.90 | 0.63, 1.28 | 0.95 | 0.62, 1.45 | ||
| Clinical classification of COVID-19 | 0.899 | — | ||||
| Asymptomatic infection | 1.00 | — | ||||
| Mild and moderate illness | 0.93 | 0.60, 1.43 | ||||
| Severe and critical illness | 0.85 | 0.38, 1.91 | ||||
| Cycle threshold value | 1.07 | 1.04, 1.11 | <0.001 | 1.06 | 1.02, 1.10 | 0.002 |
| Comorbidities | 0.059 | 0.085 | ||||
| No | 1.00 | — | 1.00 | — | ||
| Yes | 0.66 | 0.43, 1.02 | 0.66 | 0.41, 1.06 |
Notes: *All subjects, †Subjects with mild and moderate illness.